The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Open accessAbstract
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2011, based on promising results from a clinical trial in melanoma patients, the first ICI therapy ipilimumab, an anti-CTLA-4 mAb, has gained FDA approval [98].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“Antibodies against CTLA-4 (ipilimumab) or PD1 (nivolumab) have been shown to induce quick and intense tumor regression in melanoma and NSCLC patients and are currently under clinical investigation in other solid tumors, including CRC [132, 133]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [132]
In the citing paper
“Even though ICIs have shown promising results in adults, there is limited data regarding their safety in children [145].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [145]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [37]
In the citing paper
“Ipilimumab was associated with long-term survival effects (1-year and 2-year survival rate of 45.6% and 23.5%, respectively).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Treatment with Ipilimumab was associated with immune-related adverse events (irAEs) in a surprisingly high 60% of patients (Hodi et al., 2010);”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Critically, analogous to what was observed in preclinical studies, the 20% of patients whose tumors were completely cleared maintained their response for the duration of the study, with a median follow-up time of approximately 30 months.”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [32]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [10]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationManagement of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 704
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Lin R, 2008, J Clin Oncol, 26, 497s
Cited by
Sorted by citations
Items 501–600 of 1,189
Delany, I., Rappuoli, R., & Gregorio, E. D. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 458
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Self-citationThe determinants of tumour immunogenicity
Blankenstein, T. J. F., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3246 · Cited by 454
Abdel‐Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160221 · Cited by 451
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 450
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 448
The melanoma revolution: From UV carcinogenesis to a new era in therapeutics
Lo, J. A., & Fisher, D. E. (2014) · Science · doi:10.1126/science.1253735 · Cited by 447
Armand, P. A., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D., Chen, Y., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 446
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzyńska, Z., Jasiński, M., Nowis, D., & Gołąb, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 446
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Bohn, T., Rapp, S., Luther, N., Klein, M., Brühl, T.-J., Kojima, N., Lopez, P. A., Hahlbrock, J., Muth, S., Endo, S., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0226-8 · Cited by 444
The immunology of renal cell carcinoma
Diaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 447
Jiang, S., Xie, Y., Xiao, X., Kang, Z., Lin, X., Zhang, L., Li, C.-S., Qian, Y., Xu, P., Leng, X.-X., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.04.010 · Cited by 449
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Drug-Induced Interstitial Lung Disease: A Systematic Review
Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A. G. S., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M. H., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100356 · Cited by 440
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Self-citationEllis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D. J., Cortazar, P., Garrett-Mayer, E. S., Herbst, R. S., Lilenbaum, R., Sima, C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 439
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 439
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 438
Self-citationMcDermott, D. F., Drake, C. G., Sznol, M., Choueiri, T. K., Powderly, J. D., Smith, D. C., Brahmer, J. R., Carvajal, R. D., Hammers, H. J., Puzanov, I. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1041 · Cited by 437
Self-citationCutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C. A., Carson, W. E., Contreras, C. M., Daniels, G. A., DiMaio, D. J., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 437
Self-citationReversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jiménez-Baranda, S., Khan, S. A., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 436
D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 436
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 445
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 439
Epidemiology of brain metastases and leptomeningeal disease
Lamba, N., Wen, P. Y., & Aizer, A. A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab101 · Cited by 438
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 430
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S., Zha, Y., Spaapen, R. M., Zheng, Y., Corrales, L. P., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 429
Maio, M., Scherpereel, A., Calabrò, L., Aerts, J. G. J. V., Cedrés, S., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D. M., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 427
PD ‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 424
Self-citationSkin cancer and new treatment perspectives: A review
Simões, M. F., Sousa, J., & Pais, A. A. C. C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.001 · Cited by 421
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umaña, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 419
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 419
Gargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 418
Villadolid, J. J., & Amin, A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 417
Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., & Tavazoie, S. F. (2012) · Cell · doi:10.1016/j.cell.2012.10.028 · Cited by 415
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C., & Wu, T. ‐. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 414
Trafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 413
Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
Stewart, R. A., Morrow, M., Hammond, S. A., Mulgrew, K. A., Marcus, D., Poon, E., Watkins, A., Mullins, S., Chodorge, M., Andrews, J. L., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0191 · Cited by 413
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 413
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 418
Monoclonal Antibodies for Cancer Therapy
Scott, A. M., Allison, J. P., & Wolchok, J. D. (2012) · Springer eBooks · doi:10.1007/springerreference_303431 · Cited by 413
Self-citationCAR-T cells: the long and winding road to solid tumors
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0278-6 · Cited by 412
Wang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., Jin, X., Wu, Y., Yan, Y., Yang, H., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.010 · Cited by 411
Goff, S. L., Dudley, M. E., Citrin, D. E., Somerville, R. P. T., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7220 · Cited by 411
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N. T., & Raulet, D. H. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 410
Immunosuppressive cells in tumor immune escape and metastasis
Liu, Y., & Cao, X. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1376-x · Cited by 410
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G. E., & Keilholz, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv297 · Cited by 410
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 409
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 408
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Vecchio, M. D., Maio, M., Cappellini, G. C. A., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw016 · Cited by 407
Treatment of Liver CancerPreprint
Liu, C., Chen, K., & Chen, P. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021535 · Cited by 407
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Engineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 406
Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K. L., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E. O., Lutz, E. R., Liu, L. L., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 406
Huinen, Z. R., Huijbers, E. J. M., B, J. R. V. B., Nowak-Sliwinska, P. M., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 415
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 405
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 402
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R., Haque, U. J., Lipson, E. J., Bleich, K. B., Shah, A. A., Naidoo, J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209595 · Cited by 402
Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 402
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
Ye, B., Liu, X., Li, X., Kong, H.-J., Li, T., & Chen, Y. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.42 · Cited by 400
Besser, M. J., Shapira‐Frommer, R., Itzhaki, O., Treves, A. J., Zippel, D. B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0380 · Cited by 400
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
Algazi, A. P., Tsai, K. K., Shoushtari, A. N., Munhoz, R. R., Eroglu, Z., Piulats, J. M., Ott, P. A., Johnson, D. B., Hwang, J. J., DAUD, A. I., et al. (2016) · Cancer · doi:10.1002/cncr.30258 · Cited by 399
Self-citationXia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 397
The Immunoscore: Colon Cancer and Beyond
Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 399
Nomura, M., Nagatomo, R., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., Inoue, K., & Muto, M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2895 · Cited by 396
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 395
Simonaggio, A., Michot, J., Voisin, A.-L., Pavec, J. L., Collins, M., Lallart, A., Cengizalp, G., Vozy, A., Laparra, A., Varga, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1022 · Cited by 395
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Recent Advances in the Treatment of Melanoma
Curti, B. D., & Faries, M. B. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2034861 · Cited by 394
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V. S., Huse, J. T., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 393
Self-citationStructural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Żak, K. M., Grudnik, P., Magiera‐Mularz, K., Dömling, A. S. S., Dubin, G., & Holak, T. A. (2017) · Structure · doi:10.1016/j.str.2017.06.011 · Cited by 393
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 393
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C. H. H., Joseph‐Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 392
Self-citationImmune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K. S., Naidoo, J., Lin, C. T., & Danoff, S. K. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1048 · Cited by 392
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser, M., Lim, M. K., Hafler, D. A., Reardon, D. A., & Sampson, J. H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.139 · Cited by 391
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K. A., Zhang, J., Teh, C. E., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 390
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 395
Kmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Combination immunotherapy: a road map
Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0218-5 · Cited by 389
Self-citationMitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 387
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386
O'Day, S. J., Eggermont, A. M. M., Chiarion‐Sileni, V., Kefford, R. F., Grob, J., Mortier, L., Robert, C., Schachter, J., Testori, A., Mackiewicz, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5585 · Cited by 385
Self-citationXu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., Du, X., Li, T., & He, F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2690 · Cited by 385
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
O’Donnell, J. S., Massi, D., Teng, M. W. L., & Mandalà, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.015 · Cited by 384
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Grimaldi, A. M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., Giugliano, F. M., Sandomenico, F., Petrillo, A., Curvietto, M., et al. (2014) · OncoImmunology · doi:10.4161/onci.28780 · Cited by 383
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R., Cochran, A. J., Comı́n-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 383
Cellular Constituents of Immune Escape within the Tumor Microenvironment
Kerkar, S. P., & Restifo, N. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4094 · Cited by 383
Metadata
- Authors
- Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Angeles Clinic and Research Institute (US)
- Beth Israel Deaconess Medical Center (US)
- St. Mary's Medical Center (US)
- Vanderbilt University Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Colorado Cancer Center (US)
- Institut Gustave Roussy (FR)
- Essen University Hospital (DE)
- University of Mannheim (DE)
- Huntsman Cancer Institute (US)
- Mount Sinai Medical Center (US)
- The Christie Hospital (GB)
- Washington University in St. Louis (US)
- Princess Margaret Cancer Centre (CA)
- University Hospital Southampton NHS Foundation Trust (GB)
- Technical University of Munich (DE)
- Loyola University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Moffitt Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- ORCID
- Hodi, F. Stephen
- O'Day, Steven J.
- McDermott, David F.
- Sosman, Jeffrey A.
- Haanen, John B.
- Gonzalez, Rene
- Robert, Caroline
- Schadendorf, Dirk
- Hassel, Jessica C.
- Akerley, Wallace
- Lutzky, Jose
- Lorigan, Paul
- Linette, Gerald P.
- Hogg, David
- Ottensmeier, Christian H.
- Peschel, Christian
- Clark, Joseph I.
- Wolchok, Jedd D.
- Weber, Jeffrey S.
- Yellin, Michael J.
- Hoos, Axel
- Urba, Walter J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-19
- Volume
- 363
- Issue
- 8
- Pages
- 711-723
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549297
- OpenAlex
- W2097995306
- Semantic Scholar
- 51d02526aa36effc4d0eedb5649b37a0fbfc57eb
- Cited by
- 15,155
- References
- 37
- Citations by year
- 2026: 414 · 2025: 584 · 2024: 743 · 2023: 876 · 2022: 880 · 2021: 1154 · 2020: 1165 · 2019: 1106 · 2018: 1215 · 2017: 1290 · 2016: 1262 · 2015: 1265 · 2014: 1017 · 2013: 898 · 2012: 692
- FWCI
- 341.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Syracuse University
- Moffitt Cancer Center
- National Cancer Institute (K24CA097588)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, CTLA-4 blockade, immune checkpoint inhibitors, overall survival, immune-related adverse events, HLA-A*0201, cancer immunotherapy, reinduction therapy, T cell response, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Antigens, CD, Treatment Outcome, Cancer Vaccines, Kaplan-Meier Estimate, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
